News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Kristin M. Zimmerman Savill

Articles by Kristin M. Zimmerman Savill

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

BySandhya Mehta,Kristin M. Zimmerman Savill,Peng Wang,Prathamesh Pathak,Clara Lam,Jackie Kwong,Bruce Feinberg

July 28th 2024

33 Real-world Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Metastatic Breast Cancer and BRCA Mutations Treated Off-label With Talazoparib

ByReshma L. Mahtani, DO ,Jasmina Ivanova,Angelica Falkenstein,Alexander Niyazov,Joanne C. Ryan,Jonathan Kish,Ajeet Gajra,Parisa Asgarisabet,Kristin M. Zimmerman Savill

April 27th 2023

19 Real-world Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Talazoparib-Treated Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer and Germline BRCA Mutations

ByReshma L. Mahtani, DO ,Jasmina Ivanova,Angelica Falkenstein,Alexander Niyazov,Joanne C. Ryan,Jonathan Kish,Ajeet Gajra,Kristin M. Zimmerman Savill

April 18th 2022

Latest Updated Articles

19 Real-world Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Talazoparib-Treated Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer and Germline BRCA Mutations
April 18th 2022

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC